Castle Biosciences
D

CSTL

32.650
USD
-1.84
(-5.33%)
Market Open
Last updated: · Delayed 15 min
Volume
1,577
EPS
-1
Div Yield
-
P/E
-43
Market Cap
1,006,217,201
Related Instruments

Title: Castle Biosciences

Sector: Healthcare
Industry: Diagnostics & Research
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Common questions about Castle Biosciences stock